Evogene Ltd. (EVGN)

Evogene Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	9.19	5.64	1.68	0.93	1.04	0.75
Revenue Growth (YoY)	341.99%	236.72%	80.11%	-10.58%	38.11%	-56.90%
Cost of Revenue	1.68	1.69	0.91	0.77	0.57	0.33
Gross Profit	7.51	3.95	0.77	0.16	0.47	0.42
Selling, General & Admin	10.01	9.68	10.42	9.99	7.99	5.79
Research & Development	20.78	20.78	20.79	21.13	17.29	15.79
Other Operating Expenses	0.52	0	-3.5	0	0	0
Operating Expenses	31.31	30.46	27.71	31.12	25.28	21.59
Operating Income	-23.8	-26.51	-26.94	-30.95	-24.81	-21.17
Interest Expense / Income	0.59	0.97	3.33	1.41	2.95	0.56
Other Expense / Income	-2.93	-3.56	-3.72	-4.59	-4.42	-3.63
Pretax Income	-21.46	-23.91	-26.55	-27.78	-23.34	-18.09
Income Tax	0.01	-0.03	0.09	0.01	0.03	0.02
Net Income	-21.47	-23.88	-26.64	-27.79	-23.37	-18.11
Shares Outstanding (Basic)	51	46	41	40	28	26
Shares Outstanding (Diluted)	51	46	41	40	28	26
Shares Change	22.02%	10.86%	1.92%	43.59%	9.34%	0.00%
EPS (Basic)	-0.46	-0.52	-0.65	-0.69	-0.83	-0.70
EPS (Diluted)	-0.46	-0.52	-0.65	-0.69	-0.83	-0.70
Free Cash Flow	-20	-22.34	-24.85	-25.56	-20.2	-18.57
Free Cash Flow Per Share	-0.40	-0.49	-0.60	-0.63	-0.72	-0.72
Gross Margin	81.72%	70.00%	45.73%	17.53%	44.81%	55.64%
Operating Margin	-258.98%	-470.00%	-1608.42%	-3328.28%	-2385.96%	-2810.89%
Profit Margin	-233.66%	-423.39%	-1590.33%	-2988.49%	-2247.50%	-2405.31%
Free Cash Flow Margin	-217.65%	-396.03%	-1483.52%	-2748.71%	-1941.92%	-2465.60%
EBITDA	-18.22	-20.34	-20.64	-24.13	-17.66	-14.76
EBITDA Margin	-198.32%	-360.55%	-1232.18%	-2594.84%	-1698.46%	-1960.69%
Depreciation & Amortization	2.64	2.61	2.58	2.23	2.73	2.77
EBIT	-20.87	-22.95	-23.22	-26.37	-20.39	-17.53
EBIT Margin	-227.08%	-406.86%	-1386.21%	-2835.05%	-1960.67%	-2328.42%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).